Similar incidences of adverse reactions between Xolair® and placebo patients:2
| Adverse reactions¶ reported during Weeks 1-12 From the pooled CSU safety database (ASTERIA I, ASTERIA II, GLACIAL) |
||
| Adverse reactions (%) | Placebo§ | Xolair® 300 mg§ |
| Sinusitis | 2.1 | 4.9 |
| Headache | 2.9 | 6.1 |
| Arthralgia | 0.4 | 2.9 |
| Injection site reaction** | 0.8 | 2.7 |
| Adverse reactions* reported during Weeks 1-24 From the pooled CSU safety database (ASTERIA I, GLACIAL) |
||
| Upper respiratory tract infection | 3.1 | 5.7 |
¶Events occuring in ≥1% of patients in my treatment group and ≥2% more frequently in any Xolair® treatment group than in the placebo group
**Despite not showing a 2% difference to placebo, injection site reactions were included as all cases were assessed as related to study treatment
§Patients were received background treatment of non-sedenting H1-antihistamines at approved doses (ASTERIA I/II) or non-sedating H1-antihistamines (up to 4x the approved dose) plus H2-antihistamines and/or leukotiene-receptor antagonists (GLACIAL)